Delayed SAE Reporting as a Common Regulatory Audit Finding
Delayed SAE Reporting as a Common Regulatory Audit Finding Why Delayed SAE Reporting Is a Frequent Regulatory Audit Concern Introduction to SAE Reporting and Its Criticality Serious Adverse Events (SAEs) represent life-threatening or medically significant occurrences in participants during a clinical trial. Regulatory frameworks such as ICH E2A, 21 CFR Part 312.32 (FDA), and EU…
Read More “Delayed SAE Reporting as a Common Regulatory Audit Finding” »